DURHAM, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSEAmerican:NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the second quarter ended June 30, 2022.
NightHawk Biosciences Provides Second Quarter 2022 Business Update
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here